Table 1

Published studies of the association between organochlorine compounds and breast cancer

Study aYear (place)No. of cases/ controlsMean concentrations (SD)OR by categoriesPtrend
CasesControls1 (lowest)2345 (highest)
A. Published studies of the association between DDT compounds and breast cancer
Case-Control
 Adipose Tissue
  Davies (10)197529/295.4 ppm7.1 ppm
  Wasserman (11)1976 (Brazil)9/52.7 ppm6.7 ppm
  Unger (12)1982 (Denmark)14/211.2 (0.63) ppm1.2 (0.8) ppm
  Mussalo-Rauhamaa (13)1985–86 (Finland)41/330.96 (0.6) mg/kg0.98 (0.9) mg/kg
  Falck (14)1987 (United States)20/201877 (1283) ng/g c1174 (630) ng/g c
  van’t Veer (15)1991–92 (Europe)265/3411.35 μg/g1.51 μg/g1.01.140.710.480.02
  Dewailly (16)1991–92 (Canada)20/17ER−b 0.6 (0.3) μg/g0.7 (0.5) μg/g
ER+ 2.1 (2.0) μg/g
 Serum
  Wolff (17)1985–91 (United States)58/17111.0 (9.1) ppb7.7 (6.8) ppb1.01.674.372.313.680.04
  Schechter (18)1994 (Vietnam)21/2112.2 (2.4) ng/ml16.8 (4.1) ng/ml1.00.451.14
  Lopez-Carillo (19)1994–96141/141562.5 (676.2) ng/g c505.5 (567.2) ng/g c1.00.600.76
  Moysich (20)1986–91154/19211.5 (10.5) ng/g c10.8 (10.6) ng/g1.01.011.340.25
Prospective studies, nested   case-control
 Serum
  Krieger (21)1964–71 (United States)150/15043.3 (25.9) ppb43.1 (23.7) ppb1.01.311.260.43
  Hunter (22)1989–90 (United States)240/2406.01 (4.56) ppb c6.97 (5.99) ppb c1.00.880.560.730.660.22
  Hoyer (23)1976 (Denmark)240/477NA1.00.790.920.840.65
B. Published studies of the association between PCBs and breast cancer
Case-Control
 Adipose Tissue
  Wasserman (11)1976 (Brazil)9/59.1 ppm3.0 ppm
  Unger (12)1982 (Denmark)14/213.9 (1.0) ppm3.9 (1.3) ppm
18/356.47 ± 2.355.1 (2.4) ppm
  Mussalo-Rauhamaa (13)1985–86 (Finland)20/201.1 (0.6) mg/kg1.3 (0.8) mg/kg
  Falck (14)1987 (United States)41/331669 (894) ng/g1105 (424) ng/g
  Dewailly (16)1991–92 (Canada)20/17ER− 0.3 (0.7) μg/g04 (0.2) μg/g
ER+ 0.4 (0.1) μg/g
 Serum
  Wolff (17)1985–91 (United States)58/1718.0 ± 4.1 ppb6.7 ± 2.9 ppb1.05.187.024.104.350.16
  Moysich (20)1986–91154/1924.3 (2.4) mg/g c4.1 (2.2) mg/g1.00.701.140.51
Prospective studies, nested case-control
 Serum
  Krieger (21)1964–71 (United States)150/1504.4 (1.8) ppb4.8 (2.5) ppb1.01.170.940.550.590.9
  Hunter (22)1989–90 (United States)240/2405.1 (2.5) ppb c5.2 (2.3) ppb1.00.570.540.26
  Hoyer (23)1976 (Denmark)240/477NA1.00.920.781.110.77
  • a Number in parentheses cites reference.

  • b ER−, estrogen receptor negative; ER+, estrogen receptor positive; NA, not available.

  • c Lipid-adjusted.